Molecular Mechanisms of Male Reproductive Tract Development and Effects of Testosterone Therapies on Health and Reproduction
Presenter: Laura Boucai, MD (Memorial Sloan-Kettering Cancer Center)
No relevant financial relationships

Molecular Mechanisms of Male Reproductive Tract Development and Effects of Testosterone Therapies on Health and Reproduction
Presenter: Matt Ettleson, MD (University of Chicago Hospitals)
No relevant financial relationships

Molecular Mechanisms of Male Reproductive Tract Development and Effects of Testosterone Therapies on Health and Reproduction
Presenter: Dr. Pablo Knoblovits, MD (Hospital Italiano De Buenos Aires)
No relevant financial relationships

Molecular Mechanisms of Male Reproductive Tract Development and Effects of Testosterone Therapies on Health and Reproduction
Presenter: Dr. Margaret Lippincott, MD (Massachusetts General Hospital)
No relevant financial relationships

Bilateral and Unilateral Malformations of Male Reproductive Tracts in Mice with Androgen Receptor Gene Deletion in the Mesenchyme
Presenter: Shuai Jia, PhD (University of Wisconsin-Madison)
No relevant financial relationships

Bilateral and Unilateral Malformations of Male Reproductive Tracts in Mice with Androgen Receptor Gene Deletion in the Mesenchyme
Presenter: Mrs. Jillian Wilbourne, BS (University of Wisconsin Madison)
No relevant financial relationships

Bilateral and Unilateral Malformations of Male Reproductive Tracts in Mice with Androgen Receptor Gene Deletion in the Mesenchyme
Presenter: Fei Zhao, Post-Doc (University of Wisconsin-Madison)
No relevant financial relationships

Active Testosterone Treatment Impairs In Vitro Fertilization (IVF) Outcomes in a Female Mouse Model for Gender-Affirming Testosterone with Improvement in Outcomes Following Cessation of Testosterone Treatment
Presenter: Dr. Amanda R Schwartz, M.D. (University of Michigan)
No relevant financial relationships

Active Testosterone Treatment Impairs In Vitro Fertilization (IVF) Outcomes in a Female Mouse Model for Gender-Affirming Testosterone with Improvement in Outcomes Following Cessation of Testosterone Treatment
Presenter: Amanda R Schwartz, MD (University of Michigan)
No relevant financial relationships

Active Testosterone Treatment Impairs In Vitro Fertilization (IVF) Outcomes in a Female Mouse Model for Gender-Affirming Testosterone with Improvement in Outcomes Following Cessation of Testosterone Treatment
Presenter: Min Xu, PhD (University of Michigan)
No relevant financial relationships

Active Testosterone Treatment Impairs In Vitro Fertilization (IVF) Outcomes in a Female Mouse Model for Gender-Affirming Testosterone with Improvement in Outcomes Following Cessation of Testosterone Treatment
Presenter: Vasantha Padmanabhan, PhD (University of Michigan)
No relevant financial relationships

Active Testosterone Treatment Impairs In Vitro Fertilization (IVF) Outcomes in a Female Mouse Model for Gender-Affirming Testosterone with Improvement in Outcomes Following Cessation of Testosterone Treatment
Presenter: Ariella Shikanov, PhD (University of Michigan)
No relevant financial relationships

Active Testosterone Treatment Impairs In Vitro Fertilization (IVF) Outcomes in a Female Mouse Model for Gender-Affirming Testosterone with Improvement in Outcomes Following Cessation of Testosterone Treatment
Presenter: Molly B Moravek, MD (University of Michigan)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Channa Jayasena, PhD (Imperial College London Faculty of Medicine, Hammersmith Hospital, Imperial College London, UK)
Relationship: Commercial Interest(s)
  Grant Recipient: Other (fill in the blank below)
  Grant Recipient: Logixx Pharma Ltd

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Jemma Hudson, BSc (Hons), MSc (Health Services Research Unit, University of Aberdeen, UK)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Moira Cruickshank, PhD (Health Services Research Unit, University of Aberdeen, UK)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Richard Quinton, MD (Translational & Clinical Research Institute, Newcastle University and Department of Endocrinology, Diabetes & Metabolism, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon- Tyne, UK)
Relationship: Commercial Interest(s)
  Speaker: Bayer Inc.
  Speaker: Other (fill in the blank below)
  Speaker: Besins

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Lorna Aucott, PhD (Health Services Research Unit, University of Aberdeen, UK)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Shalender Bhasin, MB (Harvard Medical School, Boston, MA)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Peter Snyder, MD (Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Susan Ellenberg, PhD (Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Mathis Grossmann, MB (University of Melbourne, Australia)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Thomas Travison, PhD (Division of Gerontology, Harvard Medical School, Boston, MA)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Emily Gianatti, PhD (Department of Endocrinology, Fiona Stanley Hospital, Murdoch, Australia8. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Marielle Emmelot-Vonk, PhD (Department of Geriatrics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Erik Giltay, PhD (Department of Psychiatry, Leiden University Medical Centre, The Netherlands)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Geoff Hackett, FRCPI (Aston University Medical School Birmingham, UK)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Johan Svartberg, PhD ((1) Division of Internal Medicine, Section of Endocrinology, University Hospital of North Norway, Tromsø, Norway. (2) Tromsø Endocrine Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Kerry Hildreth, MD (Department of Medicine, Division of Geriatric Medicine, University of Colorado)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Kristina Antonic, PhD ((1) Department of Endocrinology, University Medical Centre, Ljubljana, Slovenia; (2) University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Lisa Tenover, PhD (Geriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Hui Tan, FRCPI ((1) University of Pennsylvania. (2) University of Malaya)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Leonard Marks, MD (David Geffen School of Medicine at UCLA, Los Angeles, CA)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Marianne Andersen, DmSci (Department of Endocrinology, Odense University Hospital, Odense, Denmark)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Frederick Wu, MD (Division of Diabetes, Endocrinology & Gastroenterology, Division of Diabetes, Endocrinology & Gastroenterology, University of Manchester, UK)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Waljit Dhillo, PhD (Imperial College London Faculty of Medicine, Hammersmith Hospital, Imperial College London, UK)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Siladitya Bhattacharya, MD (School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, UK)
No relevant financial relationships

Adverse Cardiovascular Events and Cause Mortality in Men During Testosterone Treatment: Individual Patient and Aggregate Data Meta-Analyses
Presenter: Miriam Brazzelli, PhD (Health Services Research Unit, University of Aberdeen, UK)
No relevant financial relationships

RBFOX2 Copy Number Variation Disrupts Urethral Development Causing Hypospadias
Presenter: Dr. Dolores Lamb, PhD, HCLD (Weill Cornell Medicine)
No relevant financial relationships

RBFOX2 Copy Number Variation Disrupts Urethral Development Causing Hypospadias
Presenter: Marisol O'Neill, PhD (University of California San Francisco School of Medicine)
No relevant financial relationships

RBFOX2 Copy Number Variation Disrupts Urethral Development Causing Hypospadias
Presenter: Fredi Ruiz Rojano, BS (New York Bioforce)
No relevant financial relationships

RBFOX2 Copy Number Variation Disrupts Urethral Development Causing Hypospadias
Presenter: Victor Ruthig, Ph.D. (Weill Cornell Medicine)
No relevant financial relationships

RBFOX2 Copy Number Variation Disrupts Urethral Development Causing Hypospadias
Presenter: Jeffrey White, MD (University of Louisville School of Medicine)
No relevant financial relationships

Sperm-carried IGF2 Downregulates Mitogens Released by Sertoli Cells: A Paracrine Mechanism of Spermatogenetic Regulation?
Presenter: Dr. Rossella Cannarella, MD (University of Catania)
No relevant financial relationships

Sperm-carried IGF2 Downregulates Mitogens Released by Sertoli Cells: A Paracrine Mechanism of Spermatogenetic Regulation?
Presenter: Francesca Mancuso, PhD (University of Perugia)
No relevant financial relationships

Sperm-carried IGF2 Downregulates Mitogens Released by Sertoli Cells: A Paracrine Mechanism of Spermatogenetic Regulation?
Presenter: Rosita Condorelli, M.D., Ph.D. (University of Catania)
No relevant financial relationships

Sperm-carried IGF2 Downregulates Mitogens Released by Sertoli Cells: A Paracrine Mechanism of Spermatogenetic Regulation?
Presenter: Iva Arato, Ph.D. (University of Perugia)
No relevant financial relationships

Sperm-carried IGF2 Downregulates Mitogens Released by Sertoli Cells: A Paracrine Mechanism of Spermatogenetic Regulation?
Presenter: Catia Bellucci, Ph.D. (University of Perugia)
No relevant financial relationships

Sperm-carried IGF2 Downregulates Mitogens Released by Sertoli Cells: A Paracrine Mechanism of Spermatogenetic Regulation?
Presenter: Sandro La Vignera, M.D., Ph.D. (University of Catania)
No relevant financial relationships

Sperm-carried IGF2 Downregulates Mitogens Released by Sertoli Cells: A Paracrine Mechanism of Spermatogenetic Regulation?
Presenter: Giovanni Luca, M.D., Ph.D. (University of Perugia)
No relevant financial relationships

Sperm-carried IGF2 Downregulates Mitogens Released by Sertoli Cells: A Paracrine Mechanism of Spermatogenetic Regulation?
Presenter: Aldo Calogero, M.D. (University of Catania)
No relevant financial relationships

In Men on Testosterone Therapy, Baseline Testosterone Level of <264 ng/dL is Associated with Greater Improvement in Body Composition, While Level of ≥264 ng/dL Favors Improvement in Metabolic Profile
Presenter: Lina Aguirre, MD (New Mexico VA Health Care System)
No relevant financial relationships

In Men on Testosterone Therapy, Baseline Testosterone Level of <264 ng/dL is Associated with Greater Improvement in Body Composition, While Level of ≥264 ng/dL Favors Improvement in Metabolic Profile
Presenter: Reina Armamento-Villarea, MD (Baylor College of Medicine)
No relevant financial relationships

In Men on Testosterone Therapy, Baseline Testosterone Level of <264 ng/dL is Associated with Greater Improvement in Body Composition, While Level of ≥264 ng/dL Favors Improvement in Metabolic Profile
Presenter: Elliot Ballato, BS (Baylor College of Medicine)
No relevant financial relationships

In Men on Testosterone Therapy, Baseline Testosterone Level of <264 ng/dL is Associated with Greater Improvement in Body Composition, While Level of ≥264 ng/dL Favors Improvement in Metabolic Profile
Presenter: Rui Chen, MD (Baylor College Of Medicine)
No relevant financial relationships

In Men on Testosterone Therapy, Baseline Testosterone Level of <264 ng/dL is Associated with Greater Improvement in Body Composition, While Level of ≥264 ng/dL Favors Improvement in Metabolic Profile
Presenter: Georgia Colleluori, MS (Baylor College of Medicine)
No relevant financial relationships

In Men on Testosterone Therapy, Baseline Testosterone Level of <264 ng/dL is Associated with Greater Improvement in Body Composition, While Level of ≥264 ng/dL Favors Improvement in Metabolic Profile
Presenter: Dr. Fnu Deepika, MD (Baylor College of Medicine)
No relevant financial relationships

In Men on Testosterone Therapy, Baseline Testosterone Level of <264 ng/dL is Associated with Greater Improvement in Body Composition, While Level of ≥264 ng/dL Favors Improvement in Metabolic Profile
Presenter: Clifford Qualls, PhD (New Mexico VA Health Care System)
No relevant financial relationships

In Men on Testosterone Therapy, Baseline Testosterone Level of <264 ng/dL is Associated with Greater Improvement in Body Composition, While Level of ≥264 ng/dL Favors Improvement in Metabolic Profile
Presenter: Dennis T. Villareal, MD (Baylor College of Medicine)
No relevant financial relationships